September 30th 2008 | Alternative/buyer beware/natural, Health care system, Treatment | 0 Comments
From the New York Times:
Can online information be trusted? The answer, increasingly, is yes. In a study earlier this year, a report in the journal Cancer looked at 343 Web pages about breast cancer that came up in online searches. The researchers found 41 inaccurate statements on 18 sites — an error rate of 5.2
READ THE FULL POST
September 21st 2008 | Patient Stories | 0 Comments
Have you checked out our September 2008 psoriasis patient profile? Lynda has lived with psoriasis for more than 15 years, but is currently enjoying treatment success. She’s not sure it will last, but is enjoying it while she can.
She also manages to be a good sport about the indignities many psoriasis patients face.
READ THE FULL POST
September 20th 2008 | Biologics, Treatment | 0 Comments
An experimental psoriasis treatment that could be approved for use in psoriasis patients by the end of 2008 edged out the leading psoriasis biologic in a 12-week head-to-head clinical trial. Ustekinumab (likely brand name, Stelara), made by Johnson & Johnson’s Centocor unit, helped more patients achieve 75% and 90% improvements in skin symptoms than
READ THE FULL POST
September 12th 2008 | Get involved | 0 Comments
“Short Sleeve Days 2008” has arrived. Even if you have not registered (and you should feel free to still do so), please consider wearing short sleeves at some point this weekend, Sept. 12-14, 2008, and educating your friends, family, colleagues and neighbors about the seriousness of psoriasis.
Rather do something from home? Why not
READ THE FULL POST
September 3rd 2008 | Patient Stories | 1 Comment
Singer songwriter LeAnn Rimes has disclosed that she has psoriasis!
September 1st 2008 | Biologics, Health care system, Psoriasis Research, Public policy issues | 0 Comments
Congress is considering several bills that would make it easier for companies to market generic versions of biologic drugs, according to a recent article in the Washington Post. Competition from generics is expected to reduce significantly the cost of expensive biologic medications. The Congressional Budget Office estimates that the availability of biologic generics would
READ THE FULL POST
